﻿<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
<channel rdf:about="http://medrxiv.org">
<admin:errorReportsTo rdf:resource="mailto:medrxiv@cshlpress.edu"/>
<title>medrxiv Subject Collection: Infectious Diseases</title>
<link>http://medrxiv.org</link>
<description>
This feed contains articles for medRxiv Subject Collection "Infectious Diseases"
</description>

<items>
<rdf:Seq>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.14.26352723v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.14.26353212v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.14.26352472v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.13.26352734v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.12.26350999v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.12.26352942v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.12.26353062v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.13.26352872v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.12.26352987v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.11.26352970v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.12.26353001v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.12.26352988v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.12.26353043v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.10.26352803v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.08.26352758v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.08.26352754v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.08.26352751v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.08.26352730v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.07.26352676v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.07.26352673v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.08.26352596v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.08.26352538v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.06.26352499v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.07.26352649v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.05.26352385v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.05.26352475v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.04.26352413v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.04.26352315v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.04.26352362v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.05.04.26352231v1?rss=1"/>
</rdf:Seq>
</items>
<prism:eIssn/>
<prism:publicationName>medrxiv</prism:publicationName>
<prism:issn/>

<image rdf:resource=""/>
</channel>
<image rdf:about="">
<title>medrxiv</title>
<url>https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png</url>
<link>http://medrxiv.org</link>
</image>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.14.26352723v1?rss=1">
<title>
<![CDATA[
Tracking Respiratory Syncytial Virus dynamics in wastewater during the 2024-2025 season in Switzerland 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.14.26352723v1?rss=1
</link>
<description><![CDATA[
Respiratory Syncytial Virus (RSV) is responsible for a substantial health burden worldwide, particularly among children and older adults. In 2023, novel immunoprophylactic interventions for RSV were approved, underscoring the need to monitor circulating RSV lineages and detect mutations that could compromise intervention effectiveness. Here, we implemented wastewater-based genomic RSV surveillance by integrating digital PCR and amplicon-based sequencing within Switzerland's national wastewater monitoring program. We tracked RSV subtypes and individual mutations across the 2024-2025 peak season in six Swiss cities. RSV-A and RSV-B co-circulated nationwide, and both exhibited similar epidemiological dynamics estimated from their subtype-specific effective reproduction numbers. No previously reported F protein mutations relevant to prophylaxis efficacy were identified. Genetic diversity analysis of wastewater-derived sequences reflected patterns previously reported in clinical data, with higher diversity in RSV-A than RSV-B and greater variability in the G compared to the F gene. These findings demonstrate the potential of wastewater-based RSV surveillance for monitoring RSV dynamics and diversity and establish a national baseline for RSV evolution during the first season following vaccine implementation in Switzerland.
]]></description>
<dc:creator><![CDATA[ Rimaite, A., de Korne-Elenbaas, J., Lison, A., Stadler, T., Julian, T. R., Beerenwinkel, N. ]]></dc:creator>
<dc:date>2026-05-18</dc:date>
<dc:identifier>doi:10.64898/2026.05.14.26352723</dc:identifier>
<dc:title><![CDATA[Tracking Respiratory Syncytial Virus dynamics in wastewater during the 2024-2025 season in Switzerland]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-18</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.14.26353212v1?rss=1">
<title>
<![CDATA[
Genomic epidemiology and transmission dynamics of plasmids carrying New Delhi metallo-β-lactamase (blaNDM) at a single hospital system over five years 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.14.26353212v1?rss=1
</link>
<description><![CDATA[
Background: Conjugative plasmids encoding New Delhi metallo-beta-lactamase (blaNDM) pose a threat for the spread of carbapenem resistance among healthcare acquired pathogens. Plasmid-associated outbreaks of blaNDM-producing bacteria can involve multiple bacterial species and persist over long time periods, making their detection and control difficult. We systematically studied the genomic epidemiology of blaNDM-encoding plasmids detected within a single hospital system over a five-year period. Methods: blaNDM-producing isolates were collected from clinical cultures as part of the Enhanced Detection System for Healthcare-Associated Transmission (EDS-HAT) genomic sequencing active surveillance program, or during infection prevention and control (IP&C) investigations. Isolates were identified as blaNDM producers by polymerase chain reaction (PCR); the presence of plasmid-encoded blaNDM genes was confirmed by sequencing on both Illumina and Oxford Nanopore platforms. Plasmids were clustered using Pling and bacterial relatedness of host isolates was evaluated with split kmer analysis. Electronic health record data were used to identify shared unit-level spatiotemporal exposures and epidemiologic links within both plasmid and host clusters. Results: We identified 61 blaNDM-producing isolates collected from 54 patients sampled between November 2020 and July 2025. Isolates belonged to 15 Enterobacterales species; Enterobacter hormaechei was the most frequently sampled species (n=23, 37%), and blaNDM-5 was the most frequently observed blaNDM allele (n=36, 59%). We observed six clusters of genetically similar blaNDM-encoding plasmids each containing 2-28 isolates, and eight singleton plasmids. The two largest plasmid clusters consisted of a highly conserved 46 kb IncX3 family blaNDM-5-encoding plasmid (n=28 plasmids, 9 species) and a more variable 98-201 kb IncC family blaNDM-1-encoding plasmid (n=12 plasmids, 6 species). Epidemiologic investigation paired with whole genome sequencing identified spatiotemporal associations between shared patient exposures and putative plasmid and bacterial transmission clusters, suggesting that unit-level exposures contribute to plasmid dissemination. Finally, analysis of publicly available sequences showed that the most prevalent plasmids detected, IncX3(blaNDM-5) and IncC(blaNDM-1), also demonstrated high global prevalence. Conclusions: This study demonstrates the diversity of blaNDM carrying plasmids within a single hospital system and their capacity to cause prolonged, multispecies outbreaks. Integrating whole genome sequencing with epidemiologic data identified unit-level spatiotemporal overlap as a likely contributor to plasmid dissemination in the hospital.
]]></description>
<dc:creator><![CDATA[ Raabe, N. J., Mills, E. J., Bapat, S., Griffith, M. P., Shutt, K., Waggle, K. D., Sundermann, A. J., Shields, R. K., Pless, L., Snyder, G. M., Harrison, L. H., Van Tyne, D. ]]></dc:creator>
<dc:date>2026-05-18</dc:date>
<dc:identifier>doi:10.64898/2026.05.14.26353212</dc:identifier>
<dc:title><![CDATA[Genomic epidemiology and transmission dynamics of plasmids carrying New Delhi metallo-β-lactamase (blaNDM) at a single hospital system over five years]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-18</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.14.26352472v1?rss=1">
<title>
<![CDATA[
Elevated baseline adiponectin levels predict increased risk of progression to tuberculosis among interferon gamma release assay-positive close contacts 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.14.26352472v1?rss=1
</link>
<description><![CDATA[
Background: Without tuberculosis preventive therapy (TPT), approximately 5% of individuals infected with M. tuberculosis progress to active tuberculosis (TB) disease. Recent studies have identified body mass index (BMI) < 25 kg/m2 as a predictor of TB progression, but additional markers are needed to better identify persons at increased risk. Methods: Close contacts of patients with culture-confirmed pulmonary TB were enrolled in the Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil cohort from 2015 to 2019 and followed for up to 24 months. Analyses were restricted to interferon-{gamma} release assay (IGRA)-positive contacts who did not receive TPT or received <30 days of isoniazid. Prediction models to identify close contacts at increased TB risk were constructed using two complementary approaches: incremental models used BMI as the base predictor and evaluated whether baseline whole-blood transcriptomic signatures, human genetic polymorphism risk scores derived from low-pass whole-genome sequencing, and BMI-related plasma biomarkers improved model discrimination. Agnostic models did not impose BMI in the model and used penalized regression for predictor selection. Results: Among 285 close contacts, 15 (5%) progressed to TB. The model with BMI as unique predictor had a C-index of 0.66 (95% confidence interval [CI] 0.55; 0.77). Adding Rajan5 or Duffy9 transcriptomic signature scores to BMI improved discrimination compared with BMI alone, with C-indices of 0.78 (95% CI 0.62; 0.99) and 0.75 (95% CI 0.61; 0.89), respectively, but did not further improve discrimination after accounting for adiponectin. Adding adiponectin to BMI increased the C-index to 0.80 (95% CI 0.68; 0.91), while adiponectin alone captured most of the discriminatory performance in agnostic models (C-index, 0.80, 95% CI 0.69; 0.91). Genetic risk scores, leptin, and the adiponectin:leptin ratio did not improve model discrimination compared with the BMI-only model. In exploratory post hoc analyses, higher adiponectin was associated with increased risk of progression to TB, with each two-fold increase associated with a higher hazard of TB (HR 2.91, 95% CI 1.73; 4.91, p < 0.001). Conclusions: Baseline adiponectin strongly predicted progression to TB among close contacts and captured most of the discriminatory information contained in epidemiological and transcriptomic variables. Its consistent selection across modelling approaches supports adiponectin as a promising biomarker for TB risk stratification.
]]></description>
<dc:creator><![CDATA[ Amorim, G., Araujo-Pereira, M., Dill-McFarland, K. A., Rangel, F. A., Mendelsohn, S. C., Figueiredo, M. C., Cordeiro-Santos, M., Rolla, V. C., Mello, F. C. Q., Rebeiro, P. F., Scriba, T. J., Hawn, T. R., Andrade, B. B., Sterling, T. R., RePORT-Brazil consortium ]]></dc:creator>
<dc:date>2026-05-18</dc:date>
<dc:identifier>doi:10.64898/2026.05.14.26352472</dc:identifier>
<dc:title><![CDATA[Elevated baseline adiponectin levels predict increased risk of progression to tuberculosis among interferon gamma release assay-positive close contacts]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-18</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.13.26352734v1?rss=1">
<title>
<![CDATA[
HPV prevalence, vaccination coverage and intention to get vaccinated among gay, bisexual, and other men who have sex with men: Evaluation of Quebec's (Canada) HPV vaccination program 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.13.26352734v1?rss=1
</link>
<description><![CDATA[
Objectives In Quebec, Canada, vaccination against human papillomavirus (HPV) has been publicly-funded since January 2016 for gay, bisexual, and other men who have sex with men (GBM) aged [&le;]26 years. The study aimed to analyze data collected in Greater Montreal (Engage study) to evaluate the HPV vaccination program for GBM in Quebec. Study Design Engage is a cohort of sexually active GBM aged [&ge;]16 recruited via respondent-driven-sampling (RDS) in Canada. Participants completed a questionnaire and tested for sexually transmitted infections. Methods RDS-II weights were applied to adjust for recruitment. Subgroups were compared using standardized mean differences. Odds ratios of HPV vaccination and prevalence ratios of anal HPV infection adjusted for potential confounders were estimated using robust regression models. Results Of 1179 participants, 309 were eligible for free HPV vaccination. Vaccine coverage among eligible GBM was 42%. Among those who disclosed same-sex sexual activity and discussed HPV vaccination with their healthcare provider, coverage reached 82%. Anal HPV prevalence among eligible GBM was 26.5% for [&ge;]1 HPV-6/11/16/18 genotypes without significant difference between vaccinated and unvaccinated individuals. Among unvaccinated GBM aged [&le;]26 who were aware of the vaccine, 60% intended to get vaccinated within the next year. Conclusions One to two years after GBM aged [&le;]26 were included in the Quebec HPV vaccination program, 42% of eligible GBM in Greater Montreal had been vaccinated. Anal HPV prevalence was high among GBM. Vaccinees were more likely to self-report a prior STI diagnosis. Offering vaccination to all preadolescents in schools appears essential to maximize vaccination benefits.
]]></description>
<dc:creator><![CDATA[ Sauvageau, C., Fourmigue, A., Ouakki, M., Lambert, G., Burchell, A. N., Coutlee, F., de Pokomandy, A., Brisson, M., Grennan, T., Dvorakova, M., Grace, D., Tan, D. H. S., Hart, T. A., Cox, J. ]]></dc:creator>
<dc:date>2026-05-17</dc:date>
<dc:identifier>doi:10.64898/2026.05.13.26352734</dc:identifier>
<dc:title><![CDATA[HPV prevalence, vaccination coverage and intention to get vaccinated among gay, bisexual, and other men who have sex with men: Evaluation of Quebec's (Canada) HPV vaccination program]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.12.26350999v1?rss=1">
<title>
<![CDATA[
Detecting simulated pathogen releases in a real-world health data set 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.12.26350999v1?rss=1
</link>
<description><![CDATA[
The purpose of electronic disease syndromic surveillance (EDSyS) systems is to detect hazardous pathogens and other unusual signals in health surveillance data before such events are identified by an individual clinician or healthcare facility. However, EDSyS systems have primarily been evaluated using simulated health surveillance data, which do not necessarily capture the richness and complexities of real-world health data. We have updated and extended an existing EDSyS system, EpiDefend, which combines ensemble forecasting and recursive Bayesian estimation in a particle filter framework that supports demographic and spatial structure. We simulated the release of several pathogens, both infectious and non-infectious, and injected the resulting cases into a real-world health data set. Here we evaluate EpiDefend's sensitivity and specificity in detecting these simulated releases, and measure the time to detection against pathogen-specific estimates of the time to clinical detection, as informed by clinicians and microbiologists. We show that for diseases where clinical diagnosis can be challenging, such as Q fever (Coxiella burnetii) and tularaemia (Francisella tularensis), EpiDefend can reliably beat the time to clinical detection. In contrast, for pathogens that can be clinically diagnosed relatively quickly, such as inhalational anthrax and pneumonic plague, it is extremely difficult to beat the time to clinical detection. Our results suggest that EpiDefend may be able to reliably detect real-world introductions or releases of some pathogens at low false-alarm rates before a clinical diagnosis would be confirmed, and this would represent a landmark achievement for EDSyS systems.
]]></description>
<dc:creator><![CDATA[ Moss, R., Testolin, M. J., Pitsaris, C., Hill, A. M., Muscatello, D. J., McCaw, J. M., Dawson, P. ]]></dc:creator>
<dc:date>2026-05-17</dc:date>
<dc:identifier>doi:10.64898/2026.05.12.26350999</dc:identifier>
<dc:title><![CDATA[Detecting simulated pathogen releases in a real-world health data set]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.12.26352942v1?rss=1">
<title>
<![CDATA[
Simulating population compliance with pandemic interventions using large language models 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.12.26352942v1?rss=1
</link>
<description><![CDATA[
Effective pandemic response requires accurate modeling of population compliance with non-pharmaceutical interventions (NPIs), yet most epidemic models treat behavioral change as fixed scenarios rather than an emergent process. Here, we test whether large language model (LLM)-based agents can generate individualized behavioral responses to time-varying NPIs and disease risk. We instantiate demographically representative agents in three U.S. cities (Boston, Denver, San Antonio) and condition them on evolving outbreak conditions and policies during the early COVID-19 pandemic, without fitting to observed mobility data. Across three frontier LLMs and their ensemble, agents generate zero-shot mobility changes across restaurants, retail, and entertainment venues, benchmarked against cellphone-derived foot-traffic records. The simulations recover average mobility trends across cities and venue types but exhibit overly narrow within-city variation. The three LLMs display distinct biases, while an ensemble approach improves robustness and overall performance. These findings establish LLM agents as a promising framework for modeling adherence to NPIs and highlight the need for further fine-tuning and empirical validation before they can support policy analysis.
]]></description>
<dc:creator><![CDATA[ Liu, R., Jong, C., Li, H., Cao, Y., Yao, Q., Yamana, T., Pei, S., Du, H. ]]></dc:creator>
<dc:date>2026-05-15</dc:date>
<dc:identifier>doi:10.64898/2026.05.12.26352942</dc:identifier>
<dc:title><![CDATA[Simulating population compliance with pandemic interventions using large language models]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.12.26353062v1?rss=1">
<title>
<![CDATA[
MODELLING SEASONAL TRENDS OF MALARIA INCIDENCE IN NASARAWA STATE, NIGERIA USING HEALTH FACILITY SURVEILLANCE DATA 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.12.26353062v1?rss=1
</link>
<description><![CDATA[
Malaria transmission in Nigeria is highly seasonal and climate-sensitive, yet routine surveillance and meteorological datasets remain underutilized for predictive modelling at subnational levels. This study modelled seasonal malaria incidence trends in Nasarawa State, Nigeria using routine surveillance and climatic data.

A retrospective ecological time-series study was conducted using monthly confirmed malaria incidence data from all 13 Local Government Areas of Nasarawa State between 2021 and 2025. Rainfall and temperature were examined as the climatic predictors. Seasonal decomposition and cross-correlation analyses were performed to identify the temporal patterns and lag structures. Seasonal Autoregressive Integrated Moving Average (SARIMA) and Seasonal Autoregressive Integrated Moving Average with Exogenous Variables (SARIMAX) models were developed using the Box-Jenkins framework. Model performance was evaluated using the Root Mean Square Error (RMSE) and Mean Absolute Percentage Error (MAPE).

Malaria incidence showed pronounced seasonal peaks, with the highest transmission occurring during the rainy season. Cross-correlation analysis identified rainfall at a one-month lag and contemporaneous temperature as significant predictors of malaria incidence. The SARIMAX model outperformed the univariate SARIMA model, achieving strong predictive accuracy (MAPE = 8.7%). Forecast projections indicate sustained transmission with a peak incidence expected between June and August 2026.

Malaria transmission in Nasarawa follows a predictable seasonal pattern that is influenced by climatic variability. Incorporating rainfall and temperature into SARIMAX models improves the forecasting performance and provides evidence supporting climate-informed malaria surveillance and preparedness in endemic settings.

PLAIN LANGUAGE SUMMARYMalaria transmission in Nigeria changes with the seasons and is influenced by weather conditions such as rainfall and temperature. This study analysed malaria surveillance data from Nasarawa State between 2021 and 2025, together with climate data, to identify seasonal patterns and predict future malaria trends. The findings showed that the number of malaria cases increased during the rainy season, particularly between June and August. A forecasting model that includes climate variables predicts malaria trends more accurately than models without climate information. These findings suggest that combining routine surveillance and climate data may improve malaria preparedness and planning in endemic areas.
]]></description>
<dc:creator><![CDATA[ Iheanacho, G. I., Ijomah, M. A., Alabere, D. I. ]]></dc:creator>
<dc:date>2026-05-15</dc:date>
<dc:identifier>doi:10.64898/2026.05.12.26353062</dc:identifier>
<dc:title><![CDATA[MODELLING SEASONAL TRENDS OF MALARIA INCIDENCE IN NASARAWA STATE, NIGERIA USING HEALTH FACILITY SURVEILLANCE DATA]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.13.26352872v1?rss=1">
<title>
<![CDATA[
A protocol for the TRACS-Liverpool study, tracking transmission of extended-spectrum beta-lactamase producing Enterobacterales across health and social care settings in the United Kingdom 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.13.26352872v1?rss=1
</link>
<description><![CDATA[
BackgroundAntimicrobial resistance (AMR) is a global public health problem. Infections caused by extended-spectrum beta-lactamase (ESBL) and carbapenemase (CP) - producing Enterobacterales (E) threaten individuals and healthcare systems worldwide. Symptomatic infection caused by Enterobacterales is typically preceded by asymptomatic colonisation and often occurs in the most vulnerable individuals, thus interrupting asymptomatic transmission is desirable. The dominant transmission routes across the healthcare continuum including hospitals, intermediate care, and long-term care facilities are not well understood.

MethodsHere we present a protocol describing a genomic surveillance framework developed for the Tracking Antimicrobial Resistance Across Care Settings (TRACS) Liverpool programme, which aims to identify critical ESBL-E transmission points in hospitals and care homes in Liverpool, UK. Our study integrates individual participant and healthcare facility data, validated standard operating procedures for taking and culturing stool, rectal, environmental, and staff samples, and genomic sequencing of ESBL-E, and statistical modelling approaches into a research framework for ESBL-E genomic surveillance.

DiscussionThere is a need for improved epidemiological and laboratory approaches to studying bacterial transmission. Drug-resistant enteric bacteria are a highly tractable marker of the movement of all enteric bacteria, and interventions designed to interrupt transmission of drug-resistant bacteria are expected to have a broader healthcare impact. This protocol provides a standardised, reproducible approach for identifying ESBL-E, tracking acquisition events, and linking clinical and environmental isolates through whole-genome sequencing.
]]></description>
<dc:creator><![CDATA[ Gallichan, S., Lewis, J. M., Forrest, S., Moore, M., Picton-Barlow, E., McKeown, C., Jewell, C. P., Todd, S., Graf, F. E., Feasey, N. A. ]]></dc:creator>
<dc:date>2026-05-15</dc:date>
<dc:identifier>doi:10.64898/2026.05.13.26352872</dc:identifier>
<dc:title><![CDATA[A protocol for the TRACS-Liverpool study, tracking transmission of extended-spectrum beta-lactamase producing Enterobacterales across health and social care settings in the United Kingdom]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.12.26352987v1?rss=1">
<title>
<![CDATA[
Vector control decision-making processes: Perspectives of twelve national malaria programmes across Africa 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.12.26352987v1?rss=1
</link>
<description><![CDATA[
BackgroundVector control is essential to malaria control and elimination. National Malaria Programmes (NMPs) must make complicated decisions about vector control in the face of evolving epidemiology, biological threats like insecticide resistance, a growing vector control toolbox, and an increasingly constrained funding landscape. The WHO recently published a manual on subnational tailoring of malaria strategies, but limited efforts have been made to understand how NMPs prioritize data and factors that impact decision-making in practice. This study explores vector control decision-making processes, enablers, and barriers across 12 African malaria programmes.

MethodsWe conducted semi-structured interviews with 13 NMP managers or designated representatives from 12 African countries. Interviews were conducted virtually via Zoom or in-person, audio-recorded, transcribed, and thematically analyzed using content analysis. Participants described the interventions in use, decision-making factors, stratification approaches, perspectives on new tools, and operational challenges.

ResultsInsecticide-treated bed nets (ITNs) and indoor residual spraying (IRS) are the core interventions in all countries, with limited but growing use of larval source management, mainly larviciding. Vector control tool selection is driven by WHO guidance, resistance profiles and patterns, epidemiological trends, operational feasibility, and donor funding priorities. Sub-national stratification is widely applied; however, limited analytic and modeling capacity hinder consistent application. Gaps in entomological data result in incomplete data availability to guide stratification. New vector control tools were perceived as promising options, albeit constrained by cost, limited evidence, regulatory delays, and community acceptability. Funding emerged as the dominant driver of decisions, shaping intervention choices regardless of country preference. Participants emphasized substantial gaps in vector control protection related to residual transmission, outdoor biting, insecticide resistance, and unprotected populations living in temporary structures or associated with high-risk occupations.

ConclusionsVector control decision-making among NMPs is shaped by an interplay of scientific evidence, operational realities, and external funding dynamics. Strengthening entomological surveillance, enhancing SNT analytic and model output interpretation capacity, securing sustainable financing, and improving community engagement are critical to advancing tailored deployment of tools. Decision-support frameworks that reflect the complexities facing NMPs may further enhance evidence-based, context-specific vector control planning.
]]></description>
<dc:creator><![CDATA[ Opiyo, M., Oppong, S. K., Vajda, E., Lobo, N. F., Tatarsky, A., Thomsen, E. ]]></dc:creator>
<dc:date>2026-05-15</dc:date>
<dc:identifier>doi:10.64898/2026.05.12.26352987</dc:identifier>
<dc:title><![CDATA[Vector control decision-making processes: Perspectives of twelve national malaria programmes across Africa]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.11.26352970v1?rss=1">
<title>
<![CDATA[
Placentas from healthy women living in a cutaneous leishmaniasis endemic region in Mexico harbor Leishmania mexicana parasites: Potential implications for pregnancy and neonatal outcomes 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.11.26352970v1?rss=1
</link>
<description><![CDATA[
BackgroundWomen living in leishmaniasis-endemic zones are regularly exposed to the sandfly vector in their environments. While case series and laboratory evidence consistently suggest transplacental transmission of Leishmania parasites with deleterious maternal-fetal effects, this issue has received insufficient attention, particularly in areas where the predominant Leishmania species is mainly associated with cutaneous disease.

Methodology/Principal FindingsWe conducted an exploratory cross-sectional study in a highly endemic zone of Tabasco, Mexico, enrolling 53 women with singleton term deliveries between April 2018 and April 2020. Placental PCR was positive in 18 (34%) participants. Buccal swabs were positive in 11 (21.2%) of 52 newborns.

Immunofluorescence confirmed intracellular amastigotes within macrophages near the vascular endothelium of PCR-positive placentas, with no surrounding inflammatory infiltration. Sequencing revealed homology to Leishmania mexicana or L. amazonensis. Birthweight percentile was modestly lower in the PCR-positive group (predicted mean 53.8% vs. 56.5%, p = 0.76), while small for gestational age showed a non-significant trend toward higher prevalence among PCR-positive cases (prevalence ratio = 2.06, 95% CI: 0.32-13.39, p = 0.45).

Conclusions/SignificanceSubclinical, dynamic transmission of Leishmania parasites typically associated with cutaneous disease was detected in this endemic zone. The presence of L. mexicana in human placentas was confirmed by immunofluorescence and sequencing, without an associated inflammatory response. These findings highlight the potential of CL-associated Leishmania species to reach the placenta and buccal mucosa of newborns, warranting further epidemiological investigation into the consequences of vertical transmission in regions with endemic CL.

Author summaryLeishmaniasis is a parasitic infection mainly known for causing skin ulcers (cutaneous leishmaniasis) or severe internal disease (visceral leishmaniasis). While congenital transmission of Leishmania has been documented in visceral disease, the potential for cutaneous species to cross the placenta has received less attention. We studied 53 pregnant women living in a highly endemic region of Tabasco, Mexico, and found that one-third harbored Leishmania DNA in their placentas, while about one-fifth of their newborns showed positive buccal swabs. Importantly, the women showed no clinical signs of cutaneous leishmaniasis, indicating that subclinical infection can still allow parasites to reach the placenta. We confirmed the presence of the parasite in placental tissue using immunofluorescence microscopy and DNA sequencing, which identified the species as Leishmania mexicana. The parasite was found inside immune cells (macrophages), without causing visible inflammation, suggesting the parasite can persist silently in placental tissue. These findings are important for women of reproductive age living in or travelling to cutaneous leishmaniasis-endemic regions, as they and their newborns may be at risk of subclinical exposure to the parasite.
]]></description>
<dc:creator><![CDATA[ Armijos, R. X., Berger, B. A., Gonzalez Ayala, A., Delgado-Hernandez, M. A., Acosta-Patino, J. L., Trinidad-Vazquez, E., Fernandez-Urrutia, L. A., Baz-Rojas, E., Mancilla-Galindo, J., Frias Selvan, C., Ortiz-Avalos, J., Avalos-Ortiz, E. C., Häberle, F., Torres-Vasquez, M., Weigel, M. M., Bartlett, A. H., Paredes, Y., Avila-Garcia, M., Aguirre Garcia, M., Galindo-Sevilla, N. ]]></dc:creator>
<dc:date>2026-05-15</dc:date>
<dc:identifier>doi:10.64898/2026.05.11.26352970</dc:identifier>
<dc:title><![CDATA[Placentas from healthy women living in a cutaneous leishmaniasis endemic region in Mexico harbor Leishmania mexicana parasites: Potential implications for pregnancy and neonatal outcomes]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.12.26353001v1?rss=1">
<title>
<![CDATA[
The germinal center B cell response to pneumococcal conjugate vaccines is antigenically restricted. 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.12.26353001v1?rss=1
</link>
<description><![CDATA[
Despite the availability of effective vaccines, pneumococcal disease remains a major global health concern. Pneumococcal vaccines are multivalent vaccines that have progressively increased in valency, a change associated with lower antibody titers to individual polysaccharide antigens. Whether increasing vaccine valency influences B cell responses through antigenic competition remains incompletely understood. Here, we studied pneumococcal polysaccharide-specific B cell responses in peripheral blood and lymph nodes of healthy adults following vaccination with the 13-valent pneumococcal conjugate vaccine. Antigen-specific memory B cells in peripheral blood expanded 2 weeks post-vaccination, whereas germinal center formation was delayed and peaked after 4 weeks. Notably, germinal center B cell responses were dominated by a limited number of specificities, in contrast to the more evenly distributed expansion observed in peripheral blood. Together, these data highlight the importance of extrafollicular responses in adult anti-pneumococcal polysaccharide immunity and provide evidence for antigenic competition during lymph node germinal center formation, which may have important implications in the context of multivalent vaccines.

SummaryUsing lymph node fine needle aspiration, the study characterizes germinal center responses to multivalent pneumococcal conjugate vaccines. Antigen-specific peripheral blood B cells expand before germinal center formation, and germinal center B cells display a restricted serotype-specific response.
]]></description>
<dc:creator><![CDATA[ de Vos, D. W., Johnson, M., Hoving, D., Loe-Sack-Sioe, G. E., Kienhuis, C., van Persijn van Meerten, E. L., Goldblatt, D., Visser, L. G., Roukens, A. H. E., Jochems, S. P. ]]></dc:creator>
<dc:date>2026-05-15</dc:date>
<dc:identifier>doi:10.64898/2026.05.12.26353001</dc:identifier>
<dc:title><![CDATA[The germinal center B cell response to pneumococcal conjugate vaccines is antigenically restricted.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.12.26352988v1?rss=1">
<title>
<![CDATA[
Predictors of treatment outcomes in adults with drug-sensitive Tuberculosis in Maharashtra, India: A retrospective study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.12.26352988v1?rss=1
</link>
<description><![CDATA[
BackgroundTuberculosis (TB) remains the leading infectious cause of death worldwide, with India accounting for nearly one-fourth of global TB cases. Ni-kshay, the countrys digital case-based TB notification platform is rich in data pertaining to the continuum of care of TB patients. This study aims to develop a standardized analytical approach to programmatic data to identify predictors of unfavourable treatment outcomes and mortality among adult drug-sensitive TB patients at the state level for Maharashtra during 2021 and 2022.

MethodsTwo separate analyses were undertaken comparing treatment success with: (1) unfavourable outcomes (death, treatment failure, loss to follow-up, regimen change, or not evaluated); and (2) mortality. Multivariate logistic regression was used to compute adjusted odds ratios (aOR) for key risk factors, adjusting for age, gender, and weight.

ResultsThe final cohort included 323,124 cases for unfavourable outcome analysis and 315,579 cases for mortality analysis. Increasing age, male gender, lower body weight, known HIV and diabetes comorbidities, tobacco and alcohol consumption, and "unknown" status for behavioural risks and comorbidity status were significantly associated with increased odds of both unfavourable outcomes and mortality.

ConclusionsThis study highlights the utility of programmatic data in identifying high-risk TB patients and offers a reproducible analytic framework.
]]></description>
<dc:creator><![CDATA[ Parthasarathy, R., Raj, Y., Majumder, N., Mitra, M., Mehra, S., Rao, R., Rajan, S. ]]></dc:creator>
<dc:date>2026-05-15</dc:date>
<dc:identifier>doi:10.64898/2026.05.12.26352988</dc:identifier>
<dc:title><![CDATA[Predictors of treatment outcomes in adults with drug-sensitive Tuberculosis in Maharashtra, India: A retrospective study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.12.26353043v1?rss=1">
<title>
<![CDATA[
Pharmacokinetics and Pharmacodynamics of (Val)Ganciclovir in Infants with Congenital Cytomegalovirus 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.12.26353043v1?rss=1
</link>
<description><![CDATA[
Ganciclovir (GCV), and its orally available pro-drug valganciclovir (VGCV), are preferred therapies for treating congenital cytomegalovirus (cCMV), however, their use carries a significant risk of neutropenia for the child. This risk limits dosing and effectiveness of VGCV, particularly in the treatment of infants with cCMV infection, who are at increased risk for sensorineural hearing loss (SNHL). We hypothesized that an improved understanding of the pharmacokinetics (PK) and pharmacodynamics (PD) of VGCV in cCMV-infected infants at risk for SNHL would inform strategies for optimizing safe and effective VGCV dosing. Participants were enrolled in one of two clinical studies interrogating the PK, safety, and efficacy of VGCV treatment in cCMV-infected infants at risk for SNHL. GCV exhibited a short median half-life of 2.02 h and the median (range) area under the 24 h concentration-time curve (AUC24) was 60.8 (26.8, 99.4) g*h/mL. An AUC24 > 70 g*h/mL was associated with an elevated risk of neutropenia (Fishers Exact p = 0.029). No associations between GCV PK and hearing outcomes were observed. Taken together, these results indicate vast inter-individual variability in GCV PK that is associated with dose-related toxicity, supporting the need for individualized dosing in the cCMV-infected population.
]]></description>
<dc:creator><![CDATA[ Lindquist-Kleissler, B., Kfoury, P., Stout, J., Wilkes, A., Schleiss, M. R., Park, A. H., Rower, J. E. ]]></dc:creator>
<dc:date>2026-05-15</dc:date>
<dc:identifier>doi:10.64898/2026.05.12.26353043</dc:identifier>
<dc:title><![CDATA[Pharmacokinetics and Pharmacodynamics of (Val)Ganciclovir in Infants with Congenital Cytomegalovirus]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.10.26352803v1?rss=1">
<title>
<![CDATA[
HOW TO INTRODUCE A NEW TB VACCINE IN ADOLESCENTS AND ADULTS: Insights from Key Stakeholders in Mozambique, Southern Africa 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.10.26352803v1?rss=1
</link>
<description><![CDATA[
Tuberculosis (TB) remains a major global health challenge, particularly in low- and middle-income countries such as Mozambique. To address this burden, promising new preventive TB vaccines targeting adolescents and adults are currently in phase III efficacy trials. This study aimed to assess stakeholders perspectives on priority high-risk groups, the challenges in reaching them, and potential strategies for delivering a TB vaccine. We conducted a qualitative study using semi-structured interviews with members of the National TB Program, the National Immunization Program, and the National Immunization Technical Advisory Group. Data were collected between March and July 2024. Our findings suggest that a TB vaccine program in Mozambique should prioritize individuals with comorbidities, especially those living with HIV or diabetes, and close contacts of TB patients, followed by healthcare workers, miners, and incarcerated populations. Although uptake is expected to vary across groups, relatively high coverage was anticipated among people living with HIV, TB contacts, and older adults, as well as healthcare workers, incarcerated individuals, formal miners, and in-school adolescents. To improve uptake, campaign-based strategies using mobile brigades were considered promising approaches to expand coverage. Stakeholder perspectives highlight the importance of prioritizing high-risk groups and adopting context-specific delivery strategies to support the effective introduction of a TB vaccine in Mozambique.

Clinical trial numbernot applicable.
]]></description>
<dc:creator><![CDATA[ Lima, A. V., Kim, D., Acacio, S., Fernandes, Q., Jose, B., Lopman, B., Garcia-Basteiro, A. L., Nelson, K. N. ]]></dc:creator>
<dc:date>2026-05-13</dc:date>
<dc:identifier>doi:10.64898/2026.05.10.26352803</dc:identifier>
<dc:title><![CDATA[HOW TO INTRODUCE A NEW TB VACCINE IN ADOLESCENTS AND ADULTS: Insights from Key Stakeholders in Mozambique, Southern Africa]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.08.26352758v1?rss=1">
<title>
<![CDATA[
Molecular Methods to Detect Vibrio cholerae and Associated Bacteriophages among Diarrheal Patients in Bangladesh 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.08.26352758v1?rss=1
</link>
<description><![CDATA[
Molecular diagnostics to detect Vibrio cholerae (Vc) may be negatively impacted by pathogen-specific lytic bacteriophage (phage) predation. To address this problem, phage detection as a proxy for pathogen detection has been proposed. However, efforts to modernize cholera diagnostics with molecular tools require addressing knowledge gaps on best practices to detect Vc and associated bacteriophages. We conducted polymerase chain reaction (PCR), quantitative PCR (qPCR), and nano-liter (nl) qPCR targeting Vc and known phages (ICP1/2/3) on stool samples collected from patients admitted at hospitals across Bangladesh. Of 4,975 patients enrolled, 2,574 diarrheal samples were collected and over 65,000 reactions were conducted, including replicates. We analyzed the results for target-specific assay alignment and then used machine learning to determine the effect of phage predation on Vc-assay alignment. Standard curve analyses were used to set qPCR-positivity thresholds at 7.3x105 CFU/mL for Vc and 1.7x103, 9.3x103, and 3.0x105 PFU/mL for ICP1, ICP2, and ICP3, respectively. Among 2,462 samples assayed by qPCR, target detection was 25.3% (623), 7.8% (193), 0.5% (13), and 5.8% (144) for Vc, ICP1, ICP2, and ICP3, respectively. There was strong alignment between assays for Vc detection ({kappa}=0.785) and moderate alignment for phage detection ({kappa}=0.609, 0.593, and 0.533 for ICP1/2/3, respectively). Phages were ranked as the first (ICP1) and third (ICP3) effectors of Vc diagnostic alignment. These findings provide insights on how to prioritize molecular methods in the cholera field as well as related less tractable diseases facing similar diagnostic challenges.

IMPORTANCEThis paper presents a comprehensive comparison of molecular methods to detect Vibrio cholerae (Vc) and associated bacteriophage (phage) which can be used as a proxy for pathogen detection. This initiative is an important step towards modernizing cholera diagnostics with molecular tools. In this study, we found that quantitative polymerase chain reaction (qPCR) represents a reasonable approach to detect Vc and associated phages balancing assay performance, cost, and accessibility. A key additional finding was that phage predation was found to be a leading factor that impacts the alignment of molecular methods to detect Vc. While we recommend qPCR be added to the cholera diagnostic toolkit, the effects of phage predation need to be accounted for in the development and evaluation of cholera diagnostics. These findings have applicability to less tractable disease where diagnostics share similar vulnerabilities.
]]></description>
<dc:creator><![CDATA[ Sriguha, I., Mu, M., Sayeed, M. A., Cato, E. T., Creasy-Marrazzo, A., Islam, K., Khabir, M. I. U., Bhuiyan, M. T. R., Begum, Y. A., Islam, M. T., Khan, Z. H., Freeman, E., Vustepalli, A., Brinkley, L., Brown, D. G., Pouchnik, D. J., Mi, K., Lin, Z., Grembi, J. A., Leung, D., Qadri, F., Khan, A. I., Nelson, E. J. ]]></dc:creator>
<dc:date>2026-05-13</dc:date>
<dc:identifier>doi:10.64898/2026.05.08.26352758</dc:identifier>
<dc:title><![CDATA[Molecular Methods to Detect Vibrio cholerae and Associated Bacteriophages among Diarrheal Patients in Bangladesh]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.08.26352754v1?rss=1">
<title>
<![CDATA[
Independent Validation of Test-Adjusted COVID-19 Incidence Estimates Using Wastewater Surveillance Data in Ontario, Canada 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.08.26352754v1?rss=1
</link>
<description><![CDATA[
BackgroundCase-based infectious disease surveillance is subject to ascertainment bias when testing intensity varies across time and population subgroups. We previously developed a regression-based test adjustment methodology using Standardized Testing Ratios (STRs) to correct for differential testing patterns in COVID-19 surveillance data. Wastewater-based surveillance (WWS) measures viral burden in the community independently of diagnostic testing behavior, making it a valuable external validation tool for test-adjusted case estimates.

MethodsWe analyzed 111 weeks of paired wastewater and case surveillance data from Ontario, Canada (July 19, 2020 to August 28, 2022). Wastewater SARS-CoV-2 signals from 107 sewersheds across 34 public health units were normalized within sewersheds and aggregated using population-weighted averages. We compared wastewater correlations with crude reported and test-adjusted case counts using Spearman rank correlations, linear regression, and negative binomial distributed lag nonlinear models (DLNM), stratified by epidemic period.

ResultsTest-adjusted cases correlated substantially more strongly with wastewater signals than crude reported cases overall (Spearman {rho} = 0.849 vs. 0.679; linear R{superscript 2} = 0.609 vs. 0.191). The advantage of test adjustment was greatest during the Omicron wave, when population-level diagnostic testing contracted sharply following PCR eligibility restrictions ({rho} = 0.924 vs. 0.604; R{superscript 2} = 0.815 vs. 0.470). DLNM incorporating the wastewater signal explained substantially more variance in test-adjusted than crude reported cases (McFadden pseudo-R{superscript 2} 0.898 vs. 0.776), despite similar lag-response structure for both outcomes.

ConclusionsWastewater surveillance provides compelling independent validation of a previously described test adjustment methodology for COVID-19 case surveillance. The agreement between wastewater signals and test-adjusted cases was strongest precisely when testing scarcity was most severe, supporting the use of test adjustment to recover accurate infection dynamics from case surveillance data during periods of changing testing access and policy.
]]></description>
<dc:creator><![CDATA[ Fisman, D., Wilson, N., Lee, C. E., Tuite, A. ]]></dc:creator>
<dc:date>2026-05-12</dc:date>
<dc:identifier>doi:10.64898/2026.05.08.26352754</dc:identifier>
<dc:title><![CDATA[Independent Validation of Test-Adjusted COVID-19 Incidence Estimates Using Wastewater Surveillance Data in Ontario, Canada]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.08.26352751v1?rss=1">
<title>
<![CDATA[
Quantifying the contributions of asymptomatic and symptomatic colonized patients to Clostridioides difficile acquisition in oncological units 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.08.26352751v1?rss=1
</link>
<description><![CDATA[
ObjectiveLeukemic and hematopoietic cell transplant patients have one of the highest incidences of C. difficile infection (CDI). While CDI patients are considered the primary source of transmission, asymptomatic colonized patients (AC) can progress to CDI or contribute to in-unit transmission. We aim to quantify the roles of CDI and AC patients in C. difficile importation and transmission within oncological units.

DesignProspective cohort study

SettingTwo leukemia and HCT transplant units in a large tertiary care hospital in the US

MethodsWe developed a stochastic, individual-based network model to simulate C. difficile acquisition and transmission. Data from cultures and nucleic acid amplification testing (NAAT) obtained at admission and weekly, and toxin enzyme immunoassay (EIA) tests used for CDI diagnosis were used to calibrate the model. Healthcare worker room assignments informed the network structure. Key parameters were estimated via particle filtering.

ResultsThe model reproduced observed weekly test counts and transmission pairs. AC patients were the primary source of new colonizations: 51% were due to importation (of those, 88% were admitted as AC), and 49% were due to transmission (AC was the source in 92% of transmissions). Sensitivity analysis showed that these findings were most influenced by the colonization rate and rates of environmental contamination and cleaning.

ConclusionsThese findings reinforce the role of AC, particularly via admission importation, in sustaining C. difficile transmission in high-risk hospital settings. Infection control focused on CDI effectively reduced onward transmission, as indicated by CDIs low contribution to new colonizations.
]]></description>
<dc:creator><![CDATA[ Savannah, C., Lee, M. M., Hink, T., Reske, K. A., Struttmann, E., Hassan Iqbal, Z., Cass, C., Olsen, M. A., Arya, S., Burnham, C.-A., Lenhart, S., Dubberke, E. R., Lanzas, C. ]]></dc:creator>
<dc:date>2026-05-12</dc:date>
<dc:identifier>doi:10.64898/2026.05.08.26352751</dc:identifier>
<dc:title><![CDATA[Quantifying the contributions of asymptomatic and symptomatic colonized patients to Clostridioides difficile acquisition in oncological units]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.08.26352730v1?rss=1">
<title>
<![CDATA[
Clinical Management of Cystic Echinococcosis in Bhutan: Current Practices, Gaps, and Recommendations 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.08.26352730v1?rss=1
</link>
<description><![CDATA[
BackgroundCystic echinococcosis (CE) is a neglected parasitic zoonosis that primarily affects marginalized populations in rural endemic regions. These populations have limited access to, and availability of, the appropriate infrastructure, resources, and skills required to treat this complex disease. This retrospective study reviewed and analyzed the clinical management of CE patients in Bhutan, based on hospital records from January 2020 to December 2024.

MethodsHospital records of 120 patients with hepatic or pulmonary CE treated between January 2020 and December 2024 in the three hospitals caring for CE patients in Bhutan were retrospectively reviewed. Data on clinical presentation, diagnosis, treatment, and outcomes were extracted from hospital records using a standardized questionnaire. Data analysis was performed using R software (version 4.4.3).

FindingsThe median age of the patients was 36 years (IQR: 21.75-53), with 60% being female. The liver was the most affected organ (70%), followed by the lungs (8%). US and CT were used in 83% for diagnostic and pre-surgical assessments. WHO-recommended CE cyst staging was performed in only 11% of cases. Pre-intervention complications were reported in 40% of patients. Treatment approaches included surgery (open or laparoscopic partial cystectomy, deroofing, and cyst drainage) combined with albendazole (ABZ) therapy (74%), PAIR in 4%, and ABZ alone in 8% of cases. Antibiotic use beyond standard perioperative prophylaxis was common (44% of cases). Post-treatment complications occurred in 23% of surgical cases, including one death; biliary leakage was the most frequent complication (55%), and more than one-third of surgical patients were discharged with drains in situ. 23% of the cohort were readmissions and 11% of the patients with hepatic CE were due to documented recurrence requiring repeat surgery. Long-term follow-up was absent, limiting the early detection and management of recurrence.

Conclusion and recommendationsThe study findings show that the care for CE patients in Bhutan urgently requires implementation of US-based cyst staging and treatment allocation, the development of infrastructure and skills for the major treatment modalities recommended by WHO guidelines and long-term follow-up to improve patient outcomes, including recurrence, and to ensure quality control of CE care. Safe and proven practices, particularly in surgery, must be prioritized over diversification. Such strategies are feasible and cost-effective.

Author SummaryCystic echinococcosis (CE) is a neglected parasitic disease that develops silently and can affect people for years before causing serious complications. It is common in rural, livestock-rearing regions, including Bhutan, where access and availability to appropriate care is limited. We reviewed hospital records of 120 patients treated for CE in Bhutan between 2020 and 2024 to understand current clinical practices and treatment outcomes. Most patients had large liver cysts and were diagnosed at a late stage, often only once complications had occurred.

US-based cyst staging was very rarely performed, and cyst-staging was not used to inform treatment decisions. Surgery combined with anti-parasitic (albendazole) therapy was the most common treatment. Postoperative complications and disease recurrence were frequent, and most patients had no long-term follow-up to attend complications and recurrences timely. Considerable variation in surgical and medical management was observed. Developing and implementing WHO-guideline-based infrastructure, resources and training for CE patient care is urgently needed.
]]></description>
<dc:creator><![CDATA[ Wangchuk, P., Hattendorf, J., Zinsstag, J., Junghanss, T. ]]></dc:creator>
<dc:date>2026-05-12</dc:date>
<dc:identifier>doi:10.64898/2026.05.08.26352730</dc:identifier>
<dc:title><![CDATA[Clinical Management of Cystic Echinococcosis in Bhutan: Current Practices, Gaps, and Recommendations]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.07.26352676v1?rss=1">
<title>
<![CDATA[
Detection of a Vibrio paracholerae Case in a Diarrheal Disease Outbreak in Costa Rica 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.07.26352676v1?rss=1
</link>
<description><![CDATA[
First documented detection of Vibrio paracholerae in a Costa Rican foodborne outbreak. Genomic analysis confirmed species identity, revealing limitations of conventional PCR and MALDI methods. Findings underscore the need for genomic surveillance to accurately characterize emerging enteropathogens and support public health systems.
]]></description>
<dc:creator><![CDATA[ Cordero-Laurent, E., Calderon-Osorno, M., Godinez-Rojas, A., Blanco-Arguedas, J., Barquero-Urena, G., Umana-Valverde, E., Oropeza-Barrios, G., Chanto-Chacon, G., Lee, C. C., Duarte-Martinez, F. J. ]]></dc:creator>
<dc:date>2026-05-12</dc:date>
<dc:identifier>doi:10.64898/2026.05.07.26352676</dc:identifier>
<dc:title><![CDATA[Detection of a Vibrio paracholerae Case in a Diarrheal Disease Outbreak in Costa Rica]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.07.26352673v1?rss=1">
<title>
<![CDATA[
Scalable deep-learning-based inference of time-varying transmission dynamics from outbreak phylogenies 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.07.26352673v1?rss=1
</link>
<description><![CDATA[
Infectious disease dynamics can be inferred from pathogen genomic data using phylodynamic methods, but the applicability of many such approaches to large data sets is constrained by computational cost. Recent deep-learning approaches to phylodynamics have improved scalability, yet challenges remain when genetic divergence is limited during fast spreading outbreaks. To address this, we use pathogen-specific models to show that deep-learning models trained on outbreak-like phylogenies can accurately estimate the reproductive number (R) when both the birth-death model and the expected phylogenetic resolution are matched to the target pathogen, highlighting the importance of realistic training conditions. Focusing on three major respiratory pathogens of public health importance (SARS-CoV-2, seasonal human influenza virus, and respiratory syncytial virus (RSV)), we introduce PhyloRt, a scalable framework for estimating the time-varying reproductive number (Rt) from large outbreak phylogenies. PhyloRt decomposes large trees into overlapping subtrees and applies a hierarchical deep-learning-based inference strategy to classify subtrees as exhibiting constant or time-varying reproduction numbers, enabling identifiable and computationally efficient estimation of Rt as a piecewise-constant trajectory through time. Applications to SARS-CoV-2 and influenza outbreaks show that PhyloRt recovers transmission dynamics consistent with estimates derived from mathematical epidemiological and Bayesian phylodynamic analyses. Our work enables scalable and rapid estimation of time-varying transmission dynamics from very large-scale outbreak genomic data sets, supporting real-time genomic epidemiology of emerging pathogens.

SignificanceEstimating changes in transmission dynamics over time is important for responding to infectious disease outbreaks. Current methods mostly rely on reported case data from epidemiological surveillance, which can be biased or incomplete due to variable testing capabilities, particularly in resource-limited settings. A complementary approach is to use viral genomes as an alternative data source. However, inferences from genomic data can be computationally intensive and have mainly been applied retrospectively. We present PhyloRt, a scalable deep-learning-based phylodynamic framework that enables fast inference of the time-varying reproductive number (Rt) from large outbreak phylogenies. Our approach is widely applicable and provides a practical approach to monitoring epidemic dynamics, complementing traditional surveillance and supporting timely public health decision-making.
]]></description>
<dc:creator><![CDATA[ XIE, R., Zhukova, A., Pena, P. G., Iglesias, G., Hu, S., Wang, J., Tsang, T. K., Dhanasekaran, V., Kraemer, M. U. G., Pybus, O. G., Gascuel, O. ]]></dc:creator>
<dc:date>2026-05-10</dc:date>
<dc:identifier>doi:10.64898/2026.05.07.26352673</dc:identifier>
<dc:title><![CDATA[Scalable deep-learning-based inference of time-varying transmission dynamics from outbreak phylogenies]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.08.26352596v1?rss=1">
<title>
<![CDATA[
Safety first: should the high tolerability of intramuscular anti-spike COVID-19 monoclonal antibody change our expectations of vaccine safety? 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.08.26352596v1?rss=1
</link>
<description><![CDATA[
IntroductionPublic and regulatory scrutiny of immunization safety has intensified in recent years. The COVID-19 pandemic has been instrumental in this. The accelerated timeline of COVID-19 vaccine development combined with the amplification of resultant side effects have proven corrosive to confidence. Unsurprisingly, COVID-19 vaccine uptake has declined year-on-year. This conflicts with the threat that infection still presents: predictors and prognoses of post-acute complications remain uncertain. Restoring public trust in these technologies will require meaningful progress in the availability and accessibility of clinical safety and pharmacovigilance data.

MethodsExpanding upon recent comparisons of COVID-19 vaccine reactogenicity, we present a post-hoc safety analysis of adintrevimab, an intramuscular (IM) anti-SARS-CoV-2 spike recombinant investigational monoclonal antibody (mAb) for the pre-exposure and post-exposure prophylaxis of COVID-19, as assessed by the multi-center, double-blind, Phase 2/3 randomized placebo-controlled EVADE study (NCT04859517). Exploratory endpoints included the incidence of [&ge;]1 systemic symptoms within 7 days of study drug administration as well as symptom number, duration and severity. Safety reporting encompassed solicited and unsolicited treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), vital signs, and clinical laboratory assessments.

ResultsEVADE study participants (n=2582) were randomized between April 2021 - January 2022. Baseline characteristics were balanced across treatment groups. Within the 7 day post-dose period, 25/1241 (2.0%) of adintrevimab recipients and 12/1242 (1.0%) of placebo recipients reported at least one systematic TEAE. Multiple systemic TEAEs were less prevalent, with 0.3% and 0.1% reporting two systemic TEAEs, and 0.1% and 0.1% reporting three TEAEs in adintrevimab and placebo groups, respectively. The majority of TEAEs reported were mild to moderate in severity, primarily involving headache (0.4% adintrevimab, 0.8% placebo), fatigue (adintrevimab 0.4%, placebo 0.2%), and nausea/vomiting (adintrevimab 0.4%, placebo 0.1%). For those participants who experienced any TEAEs in the 7 day post-dose period, mean (+/-standard deviation) number of systemic symptoms was 1.2 (0.5) for adintrevimab and 1.3 (0.6) for placebo with symptoms consistently resolving within 3 days.

ConclusionsIncreased expectations for pharmaceutical safety data generation are to be welcomed, offering patients the information they need to appropriately weigh the benefits and risks of any novel therapeutic. These analysis results support the high tolerability of IM-administered adintrevimab, with reactogenicity data broadly comparable to placebo. While the co-administration of vaccines and monoclonal antibodies limit direct comparisons between historical safety reports, findings such as these demonstrate the potential clinical value of controlled head-to-head studies such as the anticipated LIBERTY trial.
]]></description>
<dc:creator><![CDATA[ Putrino, D., Curtis, A., Leston, M., Yalcin, I., Gerlach, R., Elia, M., Mina, M. ]]></dc:creator>
<dc:date>2026-05-08</dc:date>
<dc:identifier>doi:10.64898/2026.05.08.26352596</dc:identifier>
<dc:title><![CDATA[Safety first: should the high tolerability of intramuscular anti-spike COVID-19 monoclonal antibody change our expectations of vaccine safety?]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-08</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.08.26352538v1?rss=1">
<title>
<![CDATA[
Active follow-up of Plasmodium vivax radical treatment in a mobile and hard-to-reach population in the Amazon: results from the CUREMA project. 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.08.26352538v1?rss=1
</link>
<description><![CDATA[
BackgroundEvidence from real-world implementation of follow-up and pharmacovigilance for Plasmodium vivax treatment in population scale interventions targeting asymptomatic individuals remains limited, especially among highly mobile, hard-to-reach groups. This study describes the follow-up strategy used in the CUREMA project and assesses its implementation, as well as safety, tolerability, and adherence outcomes.

MethodsThe CUREMA project implemented a PvTDA (P. vivax targeted drug administration) intervention in cross-border Amazonian settings, consisting in a full course treatment with chloroquine and primaquine (7 days) or tafenoquine (single dose), after screening its main contraindications (including semiquantitative G6PD testing); its target population was represented by artisanal and small scale migrant miners evaluated as at risk for asymptomatic P. vivax carriage. Treatment follow-up was mandatory for PvTDA participants and combined in-person visits or telephone interviews, and/or a tailored smartphone application, to be compatible with target population high mobility. Planned follow-up visits were scheduled 2, 5, and 14 days after treatment initiation. Univariate analyses described app uptake, follow-up completion, adverse events and treatment declared adherence; multivariable regression models explored factors associated with these outcomes.

ResultsAmong 294 participants who received PvTDA, 269 (91.5%) configured the smartphone application, 100 (34.0%) selected telephone follow-up and/or 44 (15.0%) selected in-person follow-up. Overall, 210/294 participants (71.4%) completed at least one follow-up questionnaire, and 81/294 (27.6%) completed the three follow-up visits At least one adverse event was recorded in 49/294 participants (16.7%); events were generally mild to moderate, and no serious adverse event was identified. The declared adherence to the 7-days chloroquine and primaquine treatment was 79.2% [95% CI 72.5-86.4].

ConclusionsActive follow-up of P. vivax radical treatment was feasible in a highly mobile, remote population when multiple complementary tools were combined. This supports pharmacovigilance and safe implementation of radical cure strategies in similarly challenging settings.
]]></description>
<dc:creator><![CDATA[ Sanna, A., Lambert, Y., Plessis, L., Carboni, C., Bardon, T., Petit-Sinturel, M., Jimeno-Maroto, I., Galindo, M., Cairo, H., Mueller, J., Bordalo Miller, J., Vreden, S., Suarez Mutis, M., Douine, M. ]]></dc:creator>
<dc:date>2026-05-08</dc:date>
<dc:identifier>doi:10.64898/2026.05.08.26352538</dc:identifier>
<dc:title><![CDATA[Active follow-up of Plasmodium vivax radical treatment in a mobile and hard-to-reach population in the Amazon: results from the CUREMA project.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-08</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.06.26352499v1?rss=1">
<title>
<![CDATA[
Ecological and molecular drivers of ESBL plasmid dissemination in Enterobacteriaceae in Vietnam 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.06.26352499v1?rss=1
</link>
<description><![CDATA[
BackgroundExtended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are among the WHOs highest-priority antibiotic-resistant pathogens. Plasmids are the main drivers of ESBL dissemination, yet their reservoirs and transmission dynamics remain poorly understood in low- and middle-income countries such as Vietnam, where infections caused by ESBL-producing bacteria are prevalent.

MethodsHere, we characterised the genetic structure of 68 ESBL-encoding conjugative plasmids isolated from the human gut microbiome (HGM) of healthy Vietnamese children. We further examined the extent of ESBL plasmid transfer between the HGM and human disease-causing Enterobacteriaceae pathogens (including Shigella sonnei, non-typhoidal Salmonella, extraintestinal pathogenic Escherichia coli ST131), as well as E. coli isolated from animals.

ResultsThe dominant plasmid Inc groups found in cephalosporin-resistant human gut bacteria were IncF, IncB/O/K/Z and IncI1, carrying mainly blaCTX-M-14, blaCTX-M-15, blaCTX-M-27 and blaCTX-M-55. These plasmids from the HGM, rather than from animal E. coli, share higher genetic similarity to plasmids in human pathogens, suggesting that human gut is the main reservoir for clinically relevant ESBL plasmids. We also found that widespread ESBL plasmid variants exhibited higher conjugation frequencies, facilitating broader geographical and host dissemination. In contrast, less mobile plasmids persisted mainly through clonal expansion of their bacterial hosts.

ConclusionsThese findings highlight the central role of the human gut as a reservoir for ESBL plasmids and provide insights into the biological factors contributing to their successful spread among pathogenic Enterobacteriaceae. Our work underscores the need for targeted interventions to reduce colonization and transmission of ESBL-producing bacteria within the human gut.
]]></description>
<dc:creator><![CDATA[ Pham, P., Quynh, P. T. M., Nguyen, Q., Tuyen, H. T., To, N. T. N., Nhi, L. T. Q., Duong, V. T., Lan, N. P. H., Baker, S., Thwaites, G., Rabaa, M. A., Chung The, H., Tang, C. M., Duy, P. T. ]]></dc:creator>
<dc:date>2026-05-08</dc:date>
<dc:identifier>doi:10.64898/2026.05.06.26352499</dc:identifier>
<dc:title><![CDATA[Ecological and molecular drivers of ESBL plasmid dissemination in Enterobacteriaceae in Vietnam]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-08</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.07.26352649v1?rss=1">
<title>
<![CDATA[
Delayed humoral kinetics but stabilization of IgG responses in common variable immunodeficiency after SARS-CoV-2 mRNA booster vaccination 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.07.26352649v1?rss=1
</link>
<description><![CDATA[
PurposePatients with common variable immunodeficiency (CVID) frequently exhibit impaired antibody responses to vaccination, yet the dynamics of humoral and cellular immunity following mRNA immunisation remain incompletely defined. This study aimed to characterise the temporal evolution of anti-SARS-CoV-2 antibody and T cell responses across successive vaccine doses in a well-characterised CVID cohort, and to identify key determinants of vaccine responsiveness in this population.

MethodsWe performed a longitudinal and cross-sectional analysis of serum and peripheral blood mononuclear cell (PBMC) samples collected from 88 CVID patients after two, three, or four doses of mRNA vaccine (Moderna/mRNA-1273 or Pfizer-BioNTech/BNT162b2). Anti-receptor-binding domain (RBD) IgG titers were quantified in relation to vaccine dose, time since last vaccination, and clinical characteristics. Vaccine-specific CD4+ and CD8+ T cell responses were assessed ex vivo using an activation-induced marker (AIM) assay by flow cytometry.

ResultsThe proportion of patients with detectable anti-RBD IgG increased from 35% after two doses to more than 80% after four doses. Boosting-dependent increases in IgG titers were observed exclusively in samples collected more than three months after the last dose, and antibody levels correlated positively with time since vaccination, consistent with delayed but progressive humoral kinetics that stabilised after the third dose. In contrast, spike-specific CD4+ and CD8+ T cell responses were rapidly induced and remained stable across all timepoints.

ConclusionVaccine-induced immunity in CVID is characterised by delayed humoral responses alongside preserved cellular immunity. Early post-vaccination serology may systematically underestimate vaccine responsiveness, and booster vaccination supports stabilisation of antibody responses in this population.
]]></description>
<dc:creator><![CDATA[ Federico, L., Loeken, R. O., Quy, K. L., Osen, J. R., Chaban, V., Nordoey, I., Skarpengland, T., Lundin, K. E., Fjellgaard Joergensen, S., Fraz, M. S. A., Aukrust, P., Lund, K. P., Tran, T. T., Nygaard Osnes, L. T., Lund-Johansen, F., Kared, H., Fevang, B., Munthe, L. A. ]]></dc:creator>
<dc:date>2026-05-08</dc:date>
<dc:identifier>doi:10.64898/2026.05.07.26352649</dc:identifier>
<dc:title><![CDATA[Delayed humoral kinetics but stabilization of IgG responses in common variable immunodeficiency after SARS-CoV-2 mRNA booster vaccination]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-08</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.05.26352385v1?rss=1">
<title>
<![CDATA[
Serum IgG antibodies induced by the synthetic carbohydrate-based conjugate vaccine candidate SF2a-TT15 against Shigella flexneri 2a cross-react with the heterologous lipopolysaccharide of Shigella flexneri 6 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.05.26352385v1?rss=1
</link>
<description><![CDATA[
BackgroundShigella flexneri 2a (SF2a) and 6 (SF6) are two of the most common S. flexneri serotypes. They have distant O-specific polysaccharide (O-SP) structures. Previous studies showed no cross-reactivity or cross-protection between the two serotypes in a guinea pig model of infection. However, partial cross-reactivity and cross-protection were reported in humans immunized with a SF2a lattice-type conjugate vaccine candidate comprising the chemically detoxified lipopolysaccharide (LPS) attached to recombinant Pseudomonas aeruginosa Exoprotein A (rEPA).

ObjectivesThis study aimed at deciphering the possible cross-reactivity with heterologous SF6 strains of antibodies induced in humans by SF2a-TT15, a sun-type SF2a conjugate vaccine candidate featuring a non-O-acetylated synthetic oligosaccharide (OS) as surrogate of the detoxified LPS. Special focus was on the impact of the O-SP non-stoichiometric O-acetylation on cross-reactivity.

MethodsSerum IgG antibody titers to LPSs from SF6 strains harboring different degrees of O-SP O-acetylation, and from Escherichia coli O147 (EC147) which shares an identical but non-O-acetylated O-SP with SF6, were measured by ELISA in 63 serum samples of volunteers receiving 2 {micro}g and 10 {micro}g OS doses of SF2a-TT15 or placebo in the frame of a phase I clinical study. Antibody in-lymphocyte-supernatants (ALS), avidity, and serum bactericidal activity (SBA) were measured in a subset of volunteers.

ResultsSF2a-TT15 induced cross-reacting IgG antibodies to all SF6 LPSs and EC147 LPS. A [&ge;]4-fold rise in anti-SF6 IgG titers was more frequent with the 10 {micro}g dose than with 2 {micro}g (50% vs 22%, p=0.045). Cross-reactivity rate was higher with the low O-acetylated SF6 O-SP than with the high O-acetylated one (50% versus 21%, p<0.05). Anti-SF6 responses correlated with homologous anti-SF2a LPS responses. Similar cross-reactivity was detected in ALS samples at day 7 after vaccination. Cross-reacting antibodies were partially functional against the heterologous SF6 parental strains, as shown by bactericidal activity and increased avidity.

ConclusionsSF2a-TT15 induces stronger SF6 cross-reactive IgG responses than the previously tested detoxified O-acetylated SF2a LPS-rEPA conjugate. While both serotypes are included in most multivalent Shigella vaccine candidates, cross-reactivity and cross-protection between SF2a and SF6 could enhance the immunogenicity and efficacy of a Shigella multivalent vaccine candidate, particularly in infants in low- and middle-income countries, the primary target population for a Shigella vaccine.
]]></description>
<dc:creator><![CDATA[ Asato, V., Meron-Sudai, S., Bialik, A., Goren, S., Mathur, S., Stahle, J., Widmalm, G., Phalipon, A., Mulard, L. A., Cohen, D. ]]></dc:creator>
<dc:date>2026-05-07</dc:date>
<dc:identifier>doi:10.64898/2026.05.05.26352385</dc:identifier>
<dc:title><![CDATA[Serum IgG antibodies induced by the synthetic carbohydrate-based conjugate vaccine candidate SF2a-TT15 against Shigella flexneri 2a cross-react with the heterologous lipopolysaccharide of Shigella flexneri 6]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-07</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.05.26352475v1?rss=1">
<title>
<![CDATA[
A direct, urine-based test to diagnose acute Lyme disease using actively secreted peptidoglycan as a biomarker 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.05.26352475v1?rss=1
</link>
<description><![CDATA[
Lyme disease is a growing and prominent human health problem caused by a group of spirochaetal bacteria that belong to the Borrelia genus. Persistent Lyme disease infection produces a multi-system disorder that may result in severe arthritis, carditis, neurological problems, and even death. Preventing severe disease requires immediate treatment, but current approaches to diagnose Lyme disease are indirect, serology-based assays that may fail early in infection. All Lyme disease-causing Borrelia species shed distinct and unique fragments of their peptidoglycan cell wall during growth. We exploited this fundamental biological process to develop an acute, urine-based diagnostic test. Using a cocktail of unique and highly specific monoclonal antibodies, our ELISA-mediated approach accurately reports on the status of an active, acute infection, in a laboratory animal model of Lyme disease, as well as humans. This rapid, simple, and innovative approach detects an active infection in as few as 3 days of transmission and in 88% of human patients yet to seroconvert--more than [~]2 weeks before serology would be positive.
]]></description>
<dc:creator><![CDATA[ Ebohon, O., Ahmad, S. S., Dressler, J., Rosario Perez, B. Y., Ocius, K. L., Pires, M. M., Nigrovic, L. E., Jutras, B. L. ]]></dc:creator>
<dc:date>2026-05-06</dc:date>
<dc:identifier>doi:10.64898/2026.05.05.26352475</dc:identifier>
<dc:title><![CDATA[A direct, urine-based test to diagnose acute Lyme disease using actively secreted peptidoglycan as a biomarker]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-06</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.04.26352413v1?rss=1">
<title>
<![CDATA[
The Birth of Influenza Immunity: High-Resolution Antibody Dynamics Driven by Maternal Antibody Waning, Vaccinations, and Infections during the first Two Years of Life 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.04.26352413v1?rss=1
</link>
<description><![CDATA[
Although infants are often described as immunological clean slates, the magnitude and durability of their first immune responses, and their effects on subsequent exposures, remains unclear. We conducted a longitudinal study of n=245 children across their first two years of life, mapping influenza antibody dynamics following vaccinations and infections. Maternal antibodies efficiently transferred to infants but exhibited different kinetics, with influenza B antibodies persisting longer than influenza A (half-life{approx}75 vs 50 days). Among infants whose maternal antibodies did not fully decay by the time of their 1st vaccination, 83-94% had no influenza A response while 59-72% had no influenza B response. To account for such maternal interference in infant vaccine responses, we formulated a personalized clinical algorithm that uses a single maternal blood draw and antibody half-lives to predict when maternal antibodies will reach undetectable levels. In addition, antibody responses varied across vaccine strains, with most infants exhibiting no response to H1N1 or H3N2 during 1st vaccination but eliciting a response after 2nd vaccination. Consequently, infants that turned 6 months old and were vaccinated in February-May - after the peak in influenza cases - showed enhanced antibody titers the following season, suggesting that [~]33% of infants in this category may benefit from late-season vaccination. Across the 60 infections captured, influenza A infections elicited strong, subtype-specific responses while influenza B led to weaker but more cross-reactive responses. Irrespective of prior infections, a strong 1st vaccine response was a predictor of a strong 2nd vaccine response, suggesting that the 1st vaccine response influences subsequent influenza immunity.
]]></description>
<dc:creator><![CDATA[ Lee, S. M., Burrell, A. R., Spranger, S., Conrey, S. C., White, B., Morrow, A. L., Payne, D. C., Staat, M. A., Einav, T. ]]></dc:creator>
<dc:date>2026-05-06</dc:date>
<dc:identifier>doi:10.64898/2026.05.04.26352413</dc:identifier>
<dc:title><![CDATA[The Birth of Influenza Immunity: High-Resolution Antibody Dynamics Driven by Maternal Antibody Waning, Vaccinations, and Infections during the first Two Years of Life]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-06</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.04.26352315v1?rss=1">
<title>
<![CDATA[
Explaining variation in antibiotic prescribing for common infections: a three-way variance decomposition using UK primary care data 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.04.26352315v1?rss=1
</link>
<description><![CDATA[
BackgroundBenchmarking has been used to target clinically unwarranted variation in antimicrobial prescribing in UK primary care. However, variation in antibiotic prescribing between general practices may be partly explained by differences in case-mix. We aimed to quantify how much variation in antibiotic prescribing for common infections was attributable to differences in prescribing between practices after accounting for case mix.

MethodsWe used the UK Clinical Practice Research Datalink (CPRD) Aurum database to identify GP consultations for 11 common infections. Three-way variance decomposition quantified the proportions of total variance attributable to patient case-mix, between practice variation, and residual unexplained variance using variables recorded in electronic medical records, across three models (no, minimal (age/sex), and full case mix adjustment). For lower respiratory tract infection (LRTI) and sore throat, external data to impute illness severity were used to estimate the potential effect of unmeasured infection severity.

FindingsWe identified 3,820,806 consultations in 2019. There was clear variability in antibiotic prescribing across practices for most conditions. In fully adjusted models, between practice variation explained 5.8-32.6% of total variance, exceeding variation attributed to case-mix in 9 out of 11 infections. Compared to no adjustment, full case-mix adjustment reduced between-practice differences, lowering their contribution to total explained variation by more than 20% in 6 of 11 infections and by 10-20% in 4 others. Minimal age-sex adjustment had little impact, with changes below 5% in 8 of 11 infections. Imputing infection severity in addition to full case-mix adjustment further reduced contribution of between-practice variance to the total variance (by 25.9% for LRTI and 8.5% for sore throat).

InterpretationDifferences in practice-level prescribing, beyond patient case-mix, call for targeted interventions and highlight the value of providing feedback at the practice level. Comprehensive case-mix adjustment, including imputed infection severity, improves the assessment of prescribing variation and supports fairer performance comparisons.

FundingWellcome Trust; NIHR

RESEARCH IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSWe searched MEDLINE for articles published between 1 January 2005 and 31 July 2025, using a combination of key terms including "antibiotic" (or "antimicrobial" or "antibacterial"), "prescribing" (or "prescription" or "use" or "utilisation" or "utilization"), "primary health care" (or "primary care" or "general practice" or "general practitioner" or "GP"), and "United Kingdom" (or "UK" or "England"). We focused on studies using patient-level data to compare antibiotic prescribing between general practices (GP practices). Most studies assessed overall prescribing or focused on a small subset of infections. Only a few examined condition-specific measures across a broader range of infections. We found no studies that decomposed variance into that caused by patient case-mix versus practice performance adjusting for case-mix across a wide range of infections.

Added value of this studyUsing individual-level data from 3.8 million consultations for eleven common infections in the UK Clinical Practice Research Datalink (CPRD) Aurum, we applied three-way variance decomposition to quantify the proportions of total variance attributable to patient case-mix, between-practice differences after adjusting for case-mix, and residual variation under three adjustment strategies (non, age-sex only, and full case-mix adjustment). There was clear variability in antibiotic prescribing across practices for most conditions. The total variance attributable to between-practice differences exceeded that attributed to case-mix in 9 out of 11 infections according, according to the fully adjusted case-mix models. Fully adjusting for case-mix based on routinely collected data substantially reduced between-practice differences, lowering their contribution to explained variance (the sum of the patient case-mix variance and between-practice variance) by more than 20% in 6 of 11 infections and by 10-20% in 4 others, whereas minimal age-sex adjustment had little impact. Between-practice differences were reduced further incorporating external information to simulate unmeasured infection severity.

Implications of all the available evidenceDifferences in practice-level prescribing, beyond patient case-mix, call for targeted interventions and highlight the value of providing feedback at the practice level. Full case-mix adjustment substantially reduces the risk of overstating between-practice differences, performing far better than adjusting for age/sex alone. Condition-specific indicators with sufficient case-mix adjustment may be more effective benchmarks of practice performance than aggregated total antibiotic use levels as general practitioners (GPs) are more likely to respond positively to comparisons they perceive as fair. In particular, acute otitis media and upper respiratory tract infection, conditions with substantial variability in antibiotic prescribing across GP practices and the highest variance attributable to adjusted between-practice differences (12.6% and 10.3%, respectively), are promising candidates for fair prescribing indicators.
]]></description>
<dc:creator><![CDATA[ Nguyen, V. N., Robotham, J. V., Walker, A. S., Eyre, D. W., Hope, R., Butler, C. C., Sharland, M., Pouwels, K. B. ]]></dc:creator>
<dc:date>2026-05-05</dc:date>
<dc:identifier>doi:10.64898/2026.05.04.26352315</dc:identifier>
<dc:title><![CDATA[Explaining variation in antibiotic prescribing for common infections: a three-way variance decomposition using UK primary care data]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-05</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.04.26352362v1?rss=1">
<title>
<![CDATA[
Early transcriptional signature in chikungunya predicts chronic arthralgia and reveals deficient antiviral response 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.04.26352362v1?rss=1
</link>
<description><![CDATA[
ObjectiveLong-term sequelae following viral infections, such as Chikungunya and SARS-CoV-2, are associated with persistent symptoms, with a notably higher prevalence in women. This study investigated the early determinants of progression to chronic chikungunya (CC) and examined the specific role of biological sex on disease outcomes.

MethodsWe analysed peripheral blood mononuclear cells (PBMCs) sampled within seven days of disease onset, recruited between 2016 and 2020. The study compared patients who eventually recovered (RC, n = 11) with those who progressed to develop CC (n = 24). We analysed gene signatures through transcriptomics and validated the results using qRT-PCR and flow cytometry

ResultsTen genes were differentially expressed between the cohorts. Specifically, the study identified an upregulation of IKZF2 (encoding Helios) in CC patients, which was confirmed by qRT-PCR. Conversely, ACKR3 (encoding a CXCL12 scavenger in the ACKR3/CXCR4/CXCL12 axis) was upregulated in RC patients and validated by flow cytometry. Furthermore, CC cases demonstrated higher viral loads and downregulation of IFN- and IFN-{gamma} pathways. We also found that immune profiles differed between men and women; specifically, interferon /{gamma} and TNF signalling pathways were upregulated in women with CC but downregulated in men with CC relative to recovered individuals.

DiscussionImmune profiles differed significantly between men and women within both the CC and RC groups. These findings suggest that progression to chronic disease is influenced by an impaired early antiviral response combined with sex-specific immune regulation. Furthermore, ACKR3 and IKZF2 are identified as potential prognostic biomarkers for chronic chikungunya.
]]></description>
<dc:creator><![CDATA[ Cerqueira-Silva, T., de Moares, L., Pereira, B. d. J., Jessica J Silva, J. J., Orge, C., Akrami, K., Souza, L., Horta, L., Rego, M., Albuquerque, A., da Silva, J. K., Cassais, P., Calvacante, L. P., Cardoso, C. R., Ramos, P. I. P., Santos, L. A., Barral-Netto, M., Barral, A., Khouri, R., Boaventura, V. S. ]]></dc:creator>
<dc:date>2026-05-05</dc:date>
<dc:identifier>doi:10.64898/2026.05.04.26352362</dc:identifier>
<dc:title><![CDATA[Early transcriptional signature in chikungunya predicts chronic arthralgia and reveals deficient antiviral response]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-05</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.05.04.26352231v1?rss=1">
<title>
<![CDATA[
Prevalence and Human Health Risks of Salmonella enterica in Baby Poultry Sold at Agricultural Supply Stores 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.05.04.26352231v1?rss=1
</link>
<description><![CDATA[
Across the United States, backyard poultry (BYP) are becoming increasingly popular as a food source as well as pets. Unfortunately, they have also been a source of annual human salmonellosis outbreaks for over a decade. Previous CDC analyses suggest baby poultry are the main source of live poultry-associated outbreaks as opposed to adult birds. However, there are few data on the frequency of pathogens, such as Salmonella enterica, in baby poultry sold to the BYP market. Further, there is a lack of data on the serovars and antimicrobial resistance (AMR) rates in these baby poultry. We collected 643 soiled bedding and shipping box samples from agricultural supply stores primarily located in Vermont. S. enterica was detected in 23.5% (151/643) of samples, with the highest rates of detection in 2021-2022. Rates of S. enterica varied by species. Turkey poult bedding samples had the highest rates of S. enterica (44.4%; 8/18), while laying chick bedding samples had the lowest (19.4%; 68/350). Meat chick bedding samples had an intermediate rate, at 36% (32/89). The most common serovar detected was Salmonella Enteritidis, which represented 51.2% (64/125) of sequenced isolates. AMR genes or AMR-associated point mutations were detected in 21.6% (27/125) of samples, but only in non-Enteritidis serovars. These data indicate that baby poultry intended for the BYP market pose a substantial risk of salmonellosis to consumers.
]]></description>
<dc:creator><![CDATA[ Larsen, K. M., Blackwell, H. L., Patch, C. A., Herren, C. S., Bears, J., Armstrong, C. M., Kanrar, S., Harper, K., Devlin, V., Martin, L., Noyes, O., Michaelides, A. M., Hood, K. A., Lunna, A., Penny, A., Armstrong, S. C., Etter, A. J. ]]></dc:creator>
<dc:date>2026-05-05</dc:date>
<dc:identifier>doi:10.64898/2026.05.04.26352231</dc:identifier>
<dc:title><![CDATA[Prevalence and Human Health Risks of Salmonella enterica in Baby Poultry Sold at Agricultural Supply Stores]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-05-05</prism:publicationDate>
<prism:section></prism:section>
</item>
</rdf:RDF>
